INS and diabetes mellitus: In Europe, the EMA granted marketing authorization for sotagliflozin in April 2019 for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus; but on 22 March 2022, the European Commission withdrew the marketing authorization in the European Union.